Company Overview
bioXcellerator is a vertically integrated regenerative medicine company with over a decade of operational history, multiple ISO certifications, and a growing intellectual property portfolio.
Built from the Clinic Up
BioXcellerator was founded in 2015 in Medellín, Colombia with a single, clear mission: to deliver the world's most advanced regenerative medicine treatments to patients who had exhausted conventional options. From the beginning, the founders understood that clinical excellence required more than great doctors — it required control over the science itself.
That insight drove every major decision over the next decade: building in-house GCP-compliant manufacturing to control cell quality, developing proprietary formulations to create defensible products, and establishing a rigorous quality management system backed by multiple ISO certifications. The result is a company that looks nothing like a typical regenerative medicine clinic — because it isn't one. BioXcellerator has become the Mayo Clinic of regenerative medicine: the destination patients and physicians turn to when they want the best.
BioXcellerator is a vertically integrated platform: three business units, one corporate structure, and a compounding competitive advantage that grows with every patient treated, every product developed, and every protocol published.
To deliver the world's most advanced regenerative medicine therapies through a vertically integrated platform that controls quality, science, and outcomes.
To become the global standard for regenerative medicine — a platform that sets the clinical, scientific, and manufacturing benchmark for the entire industry.
- ▸Scientific Integrity
- ▸Clinical Excellence
- ▸Patient Outcomes First
- ▸Transparent Operations
- ▸Continuous Innovation
Six Structural Differentiators
Vertical Integration
We control the entire value chain — from cell sourcing and GCP-compliant manufacturing to clinical delivery and IP commercialization. No other company in our category has this structure.
Multi-ISO Certified & GCP-Compliant
A decade of certified operations backed by multiple ISO certifications and Good Clinical Practices compliance. Rigorous quality management and documented patient outcomes — compliance is not a checkbox, it is a competitive moat.
Proprietary Product Portfolio
BioX Gel, BioX Skincare, Hydrogels & Scaffolds, Mitochondria Product, and Stem Cell Peptide — all manufactured in-house with growing IP protection.
Peer-Reviewed Science
Our clinical protocols are grounded in published research. BioXcellerator's outcomes data has been submitted to and published in peer-reviewed medical journals.
Strategic Location
Medellín, Colombia provides world-class medical infrastructure, regulatory flexibility for advanced cell therapies, and significantly lower operational costs than U.S. or European markets.
Market Timing
The global regenerative medicine market is projected to exceed $100B by 2030. BioXcellerator is positioned at the intersection of clinical demand and manufacturing capability.
A Decade of Deliberate Growth
Every major milestone in BioXcellerator's history reflects a deliberate strategic choice — not just clinical growth, but infrastructure building, IP development, and competitive moat construction.
BioXcellerator established in Medellín, Colombia — one of the first ISO-focused stem cell clinics in Latin America.
Achieved initial ISO certification, establishing a quality management system that remains a core differentiator.
Launched in-house GCP-compliant cell manufacturing, eliminating third-party supply dependency.
Began building proprietary product portfolio — BioX Gel, BioX Skincare, and hydrogel formulations.
Formalized three-entity corporate structure: BioXcellerator Clinic, BioX Innovations Vault, BioX Global.
5,000+ patients treated. U.S. corporate headquarters established. Capital raise initiated for next growth phase.